{"disease":{"id":"sarcoma-of-bone","name":"sarcoma of bone"},"drugs":{"marketed":[{"drug_id":"adriacin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mifamurtide","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepact","generic_name":"MIFAMURTIDE","company_name":"Takeda France SAS","drug_phase":"marketed","molecular_target":"Nucleotide-binding oligomerization domain-containing protein 2","drug_class":"mifamurtide","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"methotrexate","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"methotrexat","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03244020","title":"LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2868,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT07227961","title":"PROMIS and Mobility Evaluation in Sarcoma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT01231906","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":642,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT03284320","title":"Retrospective Study in Sarcoma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":514,"lead_sponsor_name":"University Medicine Greifswald","has_results":false},{"nct_id":"NCT03968471","title":"Chemotherapy-induced Necrosis in Ewing Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":474,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false},{"nct_id":"NCT05108298","title":"Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT06068075","title":"Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD","phase":"NA","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02306161","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":312,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02500797","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02180867","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT04845893","title":"Observational Study on Skeletal Ewing's Sarcoma","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Italian Sarcoma Group","has_results":false},{"nct_id":"NCT06074692","title":"PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05033288","title":"Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone","phase":"","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07492823","title":"Clinical Applicability of Liquid Biopsy in Chondrosarcoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT07066982","title":"Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT05024253","title":"Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Children's Cancer Hospital Egypt 57357","has_results":false},{"nct_id":"NCT03495921","title":"A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Gradalis, Inc.","has_results":true},{"nct_id":"NCT06637007","title":"Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shanxi Province Cancer Hospital","has_results":false},{"nct_id":"NCT05395741","title":"Regorafenib in Patients With Refractory Primary Bone Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Institute of Mother and Child, Warsaw, Poland","has_results":false},{"nct_id":"NCT04634227","title":"Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Iowa","has_results":false},{"nct_id":"NCT03449108","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01803152","title":"Dendritic Cell Vaccine for Children and Adults With Sarcoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Macarena De La Fuente, MD","has_results":false},{"nct_id":"NCT06737172","title":"Functional and Structural Outcomes Following Childhood Bone or Soft Tissue Sarcomas of the Lower Extremity","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":18,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT06743958","title":"Prehabilitation in Childhood Soft Tissue or Bone Sarcomas","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":16,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT06416085","title":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04420975","title":"Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04616248","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03468075","title":"Gemcitabine Plus Ascorbate for Sarcoma in Adults","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Mohammed Milhem, MBBS","has_results":true},{"nct_id":"NCT06171282","title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Shanghai Yunying Medical Technology","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}